What is the 13F Pro Quality Score for NVNO?

13F Pro ranks enVVeno Medical Corp (NVNO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NVNO's current score at https://13fpro.ai/research/NVNO (free sign-up required for the full ranking).

Where does 13F Pro source NVNO data?

All enVVeno Medical Corp fundamentals and ownership data come directly from SEC EDGAR. enVVeno Medical Corp files with the SEC under CIK 1661053. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NVNO in?

enVVeno Medical Corp (NVNO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NVNO research updated on 13F Pro?

NVNO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

enVVeno Medical Corp(NVNO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1661053 NVNO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NVNO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for enVVeno Medical Corp (NVNO), a Healthcare sector company. NVNO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), enVVeno Medical Corp reports net income of $-3.8M, free cash flow of $-3.2M. Top institutional holders of NVNO by reported 13-F value include KINGDON CAPITAL MANAGEMENT, L.L.C., CM Management,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. NVNO trades on the Nasdaq exchange and files with the SEC under CIK 1661053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVNO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for enVVeno Medical Corp directly from SEC EDGAR.

Net Income

Q1 2026

$-3.8M

Free Cash Flow

Q1 2026

$-3.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2024

FY19 $31.2KFY22 —FY23 —FY24 —

Net Income

+7.2% YoY

$-21.8MFY 2024

FY19 $-7.6MFY22 $-24.7MFY23 $-23.5MFY24 $-21.8M

Operating Income

+5.6% YoY

$-23.8MFY 2024

FY19 $-7.7MFY22 $-24.9MFY23 $-25.2MFY24 $-23.8M

EPS (Diluted)

-2231.4% YoY

$-44.53FY 2024

FY19 —FY22 $-2.20FY23 $-1.91FY24 $-44.53

Total Assets

-7.6% YoY

$45.0MFY 2024

FY19 $3.4MFY22 $41.7MFY23 $48.6MFY24 $45.0M

Op. Cash Flow

+10.7% YoY

$-16.8MFY 2024

FY19 $-5.9MFY22 $-15.6MFY23 $-18.9MFY24 $-16.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2019	FY 2018	FY 2017
Revenue	—	—	—	$31.2K -83.3%	$186.6K -55.8%	$422.1K
Net Income	$-21.8M +7.2%	$-23.5M +4.7%	$-24.7M -223.5%	$-7.6M +41.5%	$-13.0M -67.4%	$-7.8M
Operating Income	$-23.8M +5.6%	$-25.2M -1.2%	$-24.9M -224.8%	$-7.7M +2.3%	$-7.9M -28.7%	$-6.1M
EPS (Diluted)	$-44.53 -2231.4%	$-1.91 +13.2%	$-2.20	—	—	—
Total Assets	$45.0M -7.6%	$48.6M +16.7%	$41.7M +1113.1%	$3.4M -3.5%	$3.6M +60.7%	$2.2M
Operating Cash Flow	$-16.8M +10.7%	$-18.9M -20.7%	$-15.6M -164.9%	$-5.9M +7.2%	$-6.4M -51.2%	$-4.2M

AI Insight: NVNO Financial Trends

Pre-revenue NVNO continues burning cash, with equity eroding from $47M in Q3 2024 to $24M in Q1 2026 — runway is the central concern.

• No revenue recorded across all eight quarters; the company remains entirely pre-commercial.

• Equity has declined steadily from $47M in Q3 2024 to $24M in Q1 2026, a $23M erosion in six quarters.

• Operating cash burn moderated slightly to $-3M in Q4 2025 and Q1 2026, down from $-5M in Q4 2024.

⚠ At $24M equity and ~$3–4M quarterly cash burn, runway appears limited to roughly 6–8 quarters without new financing.

⚠ No debt recorded, but absence of revenue means any future capital raise likely dilutive to existing holders.

AI Insight: NVNO Ratio Trends

enVVeno remains deeply loss-making with no revenue-generating operations visible; return metrics have worsened sharply on a TTM basis to -84.2% ROIC.

• ROIC deteriorated from -52.1% in Q3 2024 to -84.2% on a TTM basis through Q1 2026, signaling accelerating capital destruction.

• ROA swung from -44.4% in Q1 2025 to -72.1% on a TTM basis, indicating rapidly rising losses relative to assets.

• OpMargin, NPM, and D/E are entirely absent across all periods, limiting visibility into operational cost structure and leverage.

⚠ TTM ROIC of -84.2% far exceeds any single quarterly reading, suggesting a large one-off cash burn event warrants scrutiny.

⚠ Absence of D/E data across all quarters leaves debt-load and dilution risk unquantifiable — a key blind spot.

Get alerted when NVNO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for enVVeno Medical Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NVNO

KINGDON CAPITAL MANAGEMENT, L.L.C.
$366.4K36,166 sh
CM Management, LLC
$361.8K35,714 sh
GEODE CAPITAL MANAGEMENT, LLC
$105.9K10,455 sh
VANGUARD CAPITAL MANAGEMENT LLC
$63.7K6,287 sh
VANGUARD FIDUCIARY TRUST CO
$22.1K2,184 sh
BlackRock, Inc.
$18.6K1,840 sh
Westside Investment Management, Inc.
$16.1K1,589 sh
Tower Research Capital LLC (TRC)
$5.5K542 sh
UBS Group AG
$2.5K243 sh
WELLS FARGO & COMPANY/MN
$1.2K114 sh

Fund	Value	Shares
KINGDON CAPITAL MANAGEMENT, L.L.C.	$366.4K	36,166
CM Management, LLC	$361.8K	35,714
GEODE CAPITAL MANAGEMENT, LLC	$105.9K	10,455
VANGUARD CAPITAL MANAGEMENT LLC	$63.7K	6,287
VANGUARD FIDUCIARY TRUST CO	$22.1K	2,184
BlackRock, Inc.	$18.6K	1,840
Westside Investment Management, Inc.	$16.1K	1,589
Tower Research Capital LLC (TRC)	$5.5K	542
UBS Group AG	$2.5K	243
WELLS FARGO & COMPANY/MN	$1.2K	114

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NVNO on your watchlist

Track score changes the day enVVeno Medical Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NVNO a good stock to buy?

13F Pro's AI-powered analysis of enVVeno Medical Corp (NVNO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVNO are available on the NVNO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NVNO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVNO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of enVVeno Medical Corp's investment landscape.